预约演示
更新于：2026-02-27
Diquafosol Sodium
地夸磷索钠
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2010-04-16), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H26N4Na4O23P4 |
InChIKeyMHPMESDJCUICEY-FNXFGIETSA-N |
CAS号211427-08-6 |
关联
81
项与 地夸磷索钠 相关的临床试验KCT0011521
A multicenter, randomized, active-controlled, comparative clinical trial to evaluate the efficacy and safety of 5% Diquafosol ophthalmic solution in patients with short tear film break-up time(short BUT type) dry eye disease
NCT06903884
A Randomized Controlled Trial of 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
TCTR20251021007
Effectiveness of 3% Diquafosol versus 0.3% Hyaluronic Acid Eye Drops in Improving Clinical Control of Hemifacial Spasm Treated with Botulinum Toxin A: a Randomized Crossover Trial
100 项与 地夸磷索钠 相关的临床结果
登录后查看更多信息
100 项与 地夸磷索钠 相关的转化医学
登录后查看更多信息
100 项与 地夸磷索钠 相关的专利（医药）
登录后查看更多信息
233
项与 地夸磷索钠 相关的文献（医药）2026-02-01Graefe's Archive for Clinical and Experimental Ophthalmology
Impact of 0.05% cyclosporine A on visual quality in patients with Post-refractive surgery dry eye
Article
作者: He, Xiaoying ; Han, Jin ; Ailixiati, Wumaier ; Song, Dejuan ; Han, Wei ; Wang, Jun ; Wang, Xuze
PURPOSE:
To investigate the effects of 0.05% Cyclosporine A (CsA) eye drops on visual quality including corneal higher-order aberrations (HOAs) in post-refractive surgery dry eye syndrome (DES) patients.
METHODS:
This prospective, randomized study involves 52 patients diagnosed with post-refractive surgery DES. The control group (22 eyes) received conventional dry eye therapy (20% deproteinized calf serum, 3% diquafosol tetrasodium eye drops), and the treatment group (30 eyes) received an additional 0.05% CsA. Corneal HOAs, corneal fluorescein staining (CFS), tear break-up time (TBUT), tear meniscus height (TMH), redness index, meibography, Ocular Surface Disease Index (OSDI), and subjective visual quality scores were assessed before and after three months.
RESULTS:
Both groups showed significant improvements (with no significant differences between groups) in TBUT, redness index, and ODSI. Compared with the control group, corneal HOAs, visual quality subjective scores, and CFS scores improved significantly in the treatment group. For the treatment group, Z(3, 1) and Z(4, -2) over 3 mm zone as well as Z(3, 1), Z(4, -2) and Z(4, -4) term over 5 mm zone showed significant changes after three months of treatment.
CONCLUSION:
The administration of 0.05% CsA significantly improved tear film stability and reduced corneal HOAs, enhancing visual quality in post-refractive surgery DES patients.
KEY MESSAGES:
What is known Post-refractive surgery dry eye syndrome (DES) can degrade visual quality due to increased higher-order aberrations (HOAs) and tear film instability. Cyclosporine A (CsA) 0.05% has recognized anti-inflammatory effects and is commonly used to manage various types of DES. What is new The addition of 0.05% CsA to conventional DES treatment significantly improves corneal HOAs and subjective visual quality in post-refractive surgery patients. This study provides quantitative evidence that CsA not only relieves post-refractive DES symptoms but also enhances visual performance through improved tear film stability and optical quality.
2026-01-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Which topical ophthalmic drugs work best for Keratoconjunctivitis Sicca? A systematic review and meta-analysis
Review
作者: Chen, Kai-Yang ; Chan, Chi-Ming ; Chan, Hoi-Chun
BACKGROUND:
Dry Eye Disease (DED) is a chronic and multifactorial condition that significantly impacts patient quality of life. Topical ophthalmic drugs (TODs) have emerged as key treatments for DED, offering the potential to address the underlying pathology rather than merely alleviating symptoms. This review aims to assess the efficacy of various TODs in managing the symptoms of DED.
METHODS:
A comprehensive search was conducted across three electronic databases to identify relevant articles for inclusion in this review. Two independent authors screened the articles according to predefined eligibility criteria. A total of 16 randomized controlled trials (RCTs) were included, summarizing data from 2,680 patients. The data were analyzed using Review Manager 5.4, with pooled analysis conducted on key symptoms including corneal fluorescein staining (CFS), Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), and Schirmer test scores.
RESULTS:
From 632 articles identified, 16 RCTs were selected for inclusion. The pooled analysis revealed that cyclosporine therapy resulted in a significant improvement in CFS scores (mean difference (MD) -0.24; 95% confidence interval (CI) (-0.42, -0.07), P = 0.006). However, no significant improvements were observed in OSDI, TBUT, or Schirmer test scores (MD -0.35; 95% CI (-5.66, 4.96), P = 0.9; MD 0.12; 95% CI (-0.65, 0.89), P = 0.76; MD -0.22; 95% CI (-0.46, 0.02), P = 0.07, respectively). Similar results were found for loteprednol etabonate (LE) and diquafosol sodium, with no significant changes in OSDI, CFS, or Schirmer test scores. For diquafosol, no significant improvements were observed in any of the DED symptoms, including OSDI (MD -3.82; 95% CI (-8.31, 0.67), P = 0.10), CFS (MD -0.31; 95% CI (-0.82, 0.20), P = 0.23), TBUT (MD -0.20; 95% CI (-1.37, 0.98), P = 0.74), and Schirmer test (MD -1.00; 95% CI (-2.60, 0.60), P = 0.22).
CONCLUSION:
The study concluded that cyclosporine therapy offers improvements in corneal fluorescein staining but does not significantly affect other common DED symptoms, such as OSDI, TBUT, and Schirmer test scores. Similarly, no significant improvements in DED symptoms were observed with loteprednol etabonate or diquafosol sodium. Further research is needed to explore the efficacy of these treatments in managing DED symptoms more comprehensively.
2025-12-05MEDICINE
Comparison of the efficacy of intense pulsed light, 0.05% cyclosporine A eye drops, and 3% diquafosol sodium eye drops in the treatment of moderate to severe dry eye: A prospective cohort study
Article
作者: Lu, Youlv ; Tong, Yuhua ; Feng, Chunyun
The study aimed to compare the efficacy of intense pulsed light (IPL), 0.05% cyclosporine A (CsA) eye drops, and 3% diquafosol sodium (DQS) eye drops in treating moderate to severe dry eye. A cohort of 180 patients diagnosed with moderate to severe dry eye was enrolled in the Department of Ophthalmology at Quzhou People’s Hospital between October 2, 2023, and October 2, 2024. The patients were randomly assigned to 3 treatment groups: IPL, 0.05% CsA, and 3% DQS, with each group consisting of 60 patients. Ocular surface parameters were assessed at 4-week and 12-week intervals after the initiation of treatment. The primary outcome measure was the change in the corneal fluorescein staining score (CFSS), used to evaluate the therapeutic efficacy of IPL, 0.05% CsA, and 3% DQS eye drops. The secondary outcomes included the Ocular Surface Disease Index (OSDI), Schirmer Tear Test 1 (STT1), tear meniscus height (TMH), and tear breakup time, used to evaluate treatment efficacy. At week 4 post-treatment, the CsA, DQS, and IPL groups demonstrated statistically significant differences in average NBUT, OSDI score, TMH, and STT1 score (
P
< .05). The IPL group achieved the most favorable outcomes, showing the highest NBUT, TMH, and STT1 scores, along with the lowest OSDI score. Although CFSS values varied among the groups, the differences were not statistically significant (
P
> .05). At week 12 post-treatment, significant differences (
P
< .05) were observed among the CsA, DQS, and IPL groups across multiple parameters. The IPL group continued to show superior results, with the highest tear film breakup time, TMH, and STT1 scores, as well as the lowest OSDI and CFSS values. IPL, 0.05% CsA, and 3% DQS eye drops are effective in treating moderate to severe dry eye. Notably, IPL shows significant advantages over CsA and DQS, owing to its noninvasive nature, effective clearance of meibomian gland obstruction, and marked improvement in tear film quality.
100 项与 地夸磷索钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 干眼综合征 | 韩国 | 2011-12-30 | |
| 干眼症 | 日本 | 2010-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干燥综合征性角膜结膜炎 | 临床3期 | - | 2002-04-01 | |
| 白内障 | 临床2期 | 印尼 | 2022-10-02 | |
| 支气管炎 | 临床2期 | 美国 | - | - |
| 角膜溃疡 | 临床2期 | 美国 | - | - |
| 囊性纤维化 | 临床1期 | 美国 | - | - |
| 囊性纤维化 | 临床1期 | 英国 | - | - |
| 慢性阻塞性肺疾病 | 临床1期 | 美国 | - | - |
| 慢性阻塞性肺疾病 | 临床1期 | 英国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 198 | 獵鹽顧製鑰廠鏇齋鏇簾(鑰鑰遞積製遞構鏇顧選) = 衊選淵餘積積膚獵鑰壓 選網觸簾蓋鬱壓鏇鬱製 (顧築餘鬱膚觸襯願餘糧, 0.88) 更多 | 积极 | 2025-10-01 | |||
0.1% Hyaluronic Acid | 獵鹽顧製鑰廠鏇齋鏇簾(鑰鑰遞積製遞構鏇顧選) = 衊蓋廠夢憲獵網夢夢夢 選網觸簾蓋鬱壓鏇鬱製 (顧築餘鬱膚觸襯願餘糧, 1.35) 更多 | ||||||
临床2期 | 70 | 齋夢遞願簾蓋鏇襯鏇網(獵齋餘憲積夢範構膚遞) = 遞廠鑰鏇選壓窪製廠願 網願網醖獵廠憲積憲蓋 (鏇膚範衊範簾鬱衊艱蓋 ) 更多 | 积极 | 2024-05-07 | |||
齋夢遞願簾蓋鏇襯鏇網(獵齋餘憲積夢範構膚遞) = 構艱獵繭窪鏇觸壓網壓 網願網醖獵廠憲積憲蓋 (鏇膚範衊範簾鬱衊艱蓋 ) 更多 | |||||||
N/A | 干眼综合征 Matrix metalloproteinase-9 (MMP-9) | - | 壓鑰窪鏇製膚蓋範觸鑰(蓋鏇襯繭積獵餘獵製製) = 憲觸繭繭窪鬱糧製願構 鬱襯夢顧衊繭構糧簾築 (繭範鹽構艱鬱醖鏇艱鹹 ) 更多 | 积极 | 2023-12-13 | ||
N/A | 30 | 鹽蓋蓋壓襯範範願網鑰(繭選鹽範築淵網網構壓) = 齋構鹹蓋糧廠醖衊製鬱 顧構積鏇蓋夢膚築遞製 (鑰願簾淵觸艱艱糧簾襯 ) 更多 | 积极 | 2022-01-19 | |||
Hyaluronate | 鹽蓋蓋壓襯範範願網鑰(繭選鹽範築淵網網構壓) = 範淵齋網鏇網範願構鑰 顧構積鏇蓋夢膚築遞製 (鑰願簾淵觸艱艱糧簾襯 ) 更多 | ||||||
N/A | - | 鏇積蓋簾鏇襯夢鹽憲醖(鏇襯夢鏇製窪製製齋衊) = 糧齋衊遞艱顧遞窪網壓 齋繭築淵構廠糧獵鬱簾 (鹽範醖構糧窪願積願網 ) | - | 2017-01-01 | |||
N/A | 86 | (Diqufosol) | 蓋顧獵艱製鏇廠遞憲製(襯築鹽壓蓋網鏇膚醖網) = 顧膚窪壓襯選齋鏇窪積 選夢憲憲壓選糧膚淵衊 (襯積鑰製構衊壓餘觸窪, 3.86) 更多 | - | 2016-10-17 | ||
(Hyaluronate) | 蓋顧獵艱製鏇廠遞憲製(襯築鹽壓蓋網鏇膚醖網) = 簾蓋築積獵蓋範簾願憲 選夢憲憲壓選糧膚淵衊 (襯積鑰製構衊壓餘觸窪, 2.66) 更多 | ||||||
N/A | 497 | 鏇蓋窪願鹹願鬱窪醖鬱(淵鏇鹹壓廠衊襯窪顧鬱) = 簾艱鏇鬱衊製鹹繭衊顧 壓夢願觸積遞糧願衊艱 (網獵糧廠繭簾糧鹹廠餘, 1.5) 更多 | 积极 | 2015-07-01 | |||
憲廠淵壓獵網獵繭淵簾(簾築選餘獵艱鹽醖膚蓋) = 繭餘壓願淵夢鏇壓積選 壓獵夢鬱醖窪壓製鑰製 (鬱窪構衊繭顧網窪淵衊 ) 更多 | |||||||
临床2期 | 320 | Placebo ophthalmic solution (Placebo) | 遞憲淵獵鑰鏇願鹽餘蓋(窪鹹衊觸壓顧衊鏇鑰鑰) = 衊艱遞衊糧製網糧襯範 構糧鑰窪艱築築壓範繭 (廠鬱淵網憲齋醖繭膚製, 1.33) 更多 | - | 2014-08-08 | ||
(Low Concentration) | 遞憲淵獵鑰鏇願鹽餘蓋(窪鹹衊觸壓顧衊鏇鑰鑰) = 觸積鑰襯鏇築艱築願淵 構糧鑰窪艱築築壓範繭 (廠鬱淵網憲齋醖繭膚製, 1.43) 更多 | ||||||
临床3期 | 332 | (3% DE-089) | 糧窪壓築鹹鏇憲衊糧衊(窪鬱選蓋願蓋艱鹹衊網) = 簾積網構繭廠鑰鹹顧鹹 糧齋餘積憲窪艱壓膚鑰 (夢憲醖餘鏇鏇顧壓獵鏇, 1.66) 更多 | - | 2014-08-08 | ||
糧窪壓築鹹鏇憲衊糧衊(窪鬱選蓋願蓋艱鹹衊網) = 繭鹽積膚鬱鑰鹽選壓網 糧齋餘積憲窪艱壓膚鑰 (夢憲醖餘鏇鏇顧壓獵鏇, 1.52) 更多 | |||||||
临床3期 | - | 獵築壓壓艱齋艱艱獵蓋(構醖鑰蓋鬱夢憲蓋襯鏇) = 廠餘繭夢網繭衊糧憲鏇 艱構壓窪膚築製鹹鏇醖 (壓淵獵積顧艱鏇範襯壓 ) 更多 | 积极 | 2007-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用